Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-137 followed by TVAX-008 in nucleos(t)ide analogue-treated HBeAg-negative chronic hepatitis B
CTR20263769Phase 2Active
- Sponsor
- HaoBo Medicine
- Start
- Oct 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137, TVAX-008 in Chronic Hepatitis B (CHB), sponsored by HaoBo Medicine. Started Oct 2026; status: active.
02
Drugs
AHB-137TVAX-008
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20263769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263769.